Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic expands ICD (implantable cardioverter defibrillator) use to AF (atrial fibrillation) patients:

This article was originally published in Clinica

Executive Summary

Medtronic has CE-marked for sale in Europe its Jewel AF implantable cardioverter defibrillator (ICD) for an expanded indication. The device, which is already available in Europe for treating patients who have atrial fibrillation (AF) combined with atrial tachycardia and ventricular tachycardia, can now be marketed for those with AF alone. Medtronic hopes to gain a similar expanded indication for the FDA-approved device in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074704

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel